Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …

Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …

Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.
1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …

The highly mutated SARS-CoV-2 Omicron (B. 1.1. 529) variant has been shown to evade a
substantial fraction of neutralizing antibody responses elicited by current vaccines that …

Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …

During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been
deployed globally. We investigated whether antibodies stimulated by mRNA vaccination …

Objective To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE)
against concerned outcomes in real-world settings. Methods Studies reporting COVID-19 VE …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …